Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?
- In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, with earnings per share rising year over year, while six‑month revenue reached US$1.77 billion and net income US$342.3 million.
- The company also deepened its leadership bench with new senior appointments in market access, intellectual property, finance, and business development, aligning management capabilities with its broadened commercial portfolio and acquisition-driven growth.
- We’ll now examine how Neurocrine’s strong earnings beat and raised INGREZZA sales guidance affect its existing investment narrative and future expectations.
Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
Neurocrine Biosciences Investment Narrative Recap
To own Neurocrine, you have to believe its neurology portfolio, led by INGREZZA, can offset pricing pressure, payer scrutiny, and product concentration risk as it grows. The latest earnings beat and higher INGREZZA guidance reinforce the near term earnings catalyst, but do not remove the key risk around US pricing and reimbursement pressure, especially as reforms and payer tightening continue to play out.
The most relevant recent announcement here is Neurocrine’s hiring of a new Senior Vice President of Market Access. For a business where Medicare contracting, rebates, and access hurdles can directly shape INGREZZA and CRENESSITY sales, having dedicated leadership on global market access may meaningfully influence how well the company manages pricing pressure and payer barriers around its main catalysts.
Yet beneath the strong quarter, investors should be aware that growing dependence on payer approvals and Medicare pricing could still...
Read the full narrative on Neurocrine Biosciences (it's free!)
Neurocrine Biosciences’ narrative projects $5.1 billion revenue and $1.5 billion earnings by 2029. This requires 18.0% yearly revenue growth and an earnings increase of about $831 million from $668.6 million today.
Uncover how Neurocrine Biosciences' forecasts yield a $192.88 fair value, a 16% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts already expected Neurocrine to reach about US$6.4 billion in revenue and US$2.7 billion in earnings by 2029, so this earnings beat and raised INGREZZA guidance may either reinforce that rare disease expansion story or highlight how exposed you still are to tougher CRENESSITY reimbursement over time, depending on how you see the trade off.
Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth just $192.88!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.
No Opportunity In Neurocrine Biosciences?
Our top stock finds are flying under the radar-for now. Get in early:
- Find 55 companies with promising cash flow potential yet trading below their fair value.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com